Table 1.

Summary of potential peptide therapies for Influenza.

Target protein	Peptide Name	Sequence	Derived from	IC50	Assay Format Tested	Phase	Reference
HA	LL-37	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	Cathelicidin	0.9−11.3 μM	Neutralization assay	Pre-clinical	[197]
	GI-20	GIKEFKRIVQRIKDFLRNLV	AMP (LL-37)	1.6−3.2 μM	Neutralization assay	Pre-clinical
	P1, P2, P3	SKHSSLDCVLRP (1), AGDDQGLDKCVPNSKEK (2), and NGESSADWAKN (3)	Lactoferrin	PM-FM	Neutralization assay	Pre-clinical	[7]
	Tetrapeptides	Peptide 14 (VLRP)	Lactoferrin	fM range	Neutralization assay	Pre-clinical	[184]
		Peptide 15 (SLDC) and	SKHSSLDCVLRP (1),
		Peptide 17 (SKHS)
	P9	NGAICWGPCPTAFRQIGNCGHFKVRCCKIR	mouse β-defensin-4	1.5−4.8 μg/mL	plaque reduction assay	Pre-clinical	[231]
	EB	RRKKAAVALLPAVLLALLAP	fibroblast growth factor 4	3−10 μM	hemagglutination inhibition assay	Pre-clinical	[106]
	FP-4	RRKKWLVFFVIFYFFR	Tyrosine kinase inhibitor peptide	0.05−0.13 μM	plaque-reduction assay	Pre-clinical	[5]
	Flufirvitide-3	- *	fusion initiation region	nM range	plaque inhibition assay	Phase 1	[67]
	P7	(Nva-Orn-meLEYchlFEWLS-βAla	Neutralizing antibodies	30−70 nM	AlphaLisa competition binding assay	Pre-clinical	[108]
	C-18-s2(1−5)	C17H35CO-ARLPR-NH	Phage library	1.6−1.9 μM	plaque inhibition assay	Pre-clinical	[137]
NA	peptide P	PGEKGPSGEAGTAGPPGTPGPQGL	Cod skin hydrolysates	3.5 mg/mL	NA inhibitory assay	Pre-clinical	[118]
	P2	errKPAQP	Binding pockets of oseltamivir in NA	4.25 μM	NA inhibitory assay Cytopathic effect (CPE) assay	Pre-clinical	[34]

*not available in the literature.